SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalAvadel AVDL


Previous 10 Next 10 
To: rkrw who wrote (205)3/3/2008 2:56:33 PM
From: sammaster
   of 240
 
any update on recent coreg cr scripts?

thanks in advance...

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: sammaster who wrote (211)3/3/2008 4:43:07 PM
From: rkrw
   of 240
 
44,900 scripts total for the week of 2/22.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: rkrw who wrote (212)3/3/2008 6:41:50 PM
From: sammaster
   of 240
 
thanks for reply...

thats only about a 5% increase in 4 months...

flml just came out with earnings today...
only about 2 million in royalties from coreg cr(high margin) and maybe about 3 million fromm manufacturing coreg cr(low margin)..
guess coreg will provide the cash flow so they dont have to raise cash, but not quite the cash cow that a lot of people were expecting...
10 medusa contracts is great but they will take years to get to market...
maybe if flml gets a final washout selling it will be worth it to put away for a few years in a long term portfolio...

Share RecommendKeepReplyMark as Last Read


From: DewDiligence_on_SI3/24/2008 4:27:03 PM
   of 240
 
New Paragraph-IV challenge disclosed by FDA on Coreg CR.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: DewDiligence_on_SI who wrote (214)6/11/2009 9:11:20 PM
From: Arthur Radley
   of 240
 
There seems to be some under the radar movement in FLML.....maybe there is more on the horizon, finally for them.

Transcript of last Q report.....promises several deals coming.
seekingalpha.com

Share RecommendKeepReplyMark as Last Read


From: Arthur Radley9/1/2009 4:39:35 PM
   of 240
 
Stock pulled back today in overall down market........but with new 52 week high last week they seem to be moving under the radar. They continue to build cash with growing deals, so maybe it's time to revisit this old time favorite.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (216)9/18/2009 12:22:08 PM
From: Arthur Radley
   of 240
 
Took a position in the stock this morning...@$9.47

Share RecommendKeepReplyMark as Last Read


From: Arthur Radley9/22/2009 10:45:22 AM
   of 240
 
cc.talkpoint.com

Would suggest all listen to the UBS presentation this morning. The project announced for the funding being done by the French government is important..........listen to Willard's explanation, plus the 'promised' two new projects this Q and next Q.

One has to appreciate Willard's constant reminder of the 'shareholders' in the company plans. Sort of novel to have a CEO being concerned about the investors. (:>)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (218)11/4/2009 8:47:38 AM
From: Arthur Radley
   of 240
 
Flamel Technologies Announces Licensing Agreement with Pfizer
8:00 am ET 11/04/2009 - Business Wire
LYON, France--(BUSINESS WIRE)--

Flamel Technologies (Nasdaq:FLML) today announced that Pfizer (NYSE:PFE)

has exercised its option to license Flamel's Medusa(R) technology for the

development of a controlled release formulation of an already-marketed

therapeutic protein. Flamel will receive a further payment of $1 million

pursuant to the exercise of the license; Pfizer will pay all development

costs of the program, including milestone payments and royalties on any

worldwide commercial sales. The program was begun in 2007 with Wyeth,

which was acquired by Pfizer last month. The program leverages Flamel's

ability to create controlled-release formulations of therapeutic

proteins for intravenous administration.

Stephen H. Willard, Flamel's chief executive officer, commented,

"Pfizer's decision to move forward follows a two year evaluation period

during which Flamel has developed and demonstrated an aspect of the

Medusa platform which allows us to work on controlled release

formulations of molecules that are injected intravenously. We believe

that this work has the potential to benefit patients in many ways, not

least by lessening the time and costs associated with frequent hospital

visits."

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (219)11/4/2009 1:31:17 PM
From: Arthur Radley
   of 240
 
Q report is now on schedule for Friday of this week. The key will be whether they can continue to build their cash position. From the 1Q to the 2Q they increased cash from $39.1 million to $45.0 Million, so with several previously announced deals being booked during the 3rdQ it will be important to see if they can continue to keep cost down and build their cash reserves. Stock has bounced with PFE deal announcement today, but volume is only average........so appears new money coming in will be keyed to Q report.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10